Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | AGXT | P21549 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23453280 | 0.88 | KDM4E (0.59) | NPC1MAPTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL23412203 | 0.82 | KDM4E (0.57) | NPC1MAPTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL2439028 | 0.81 | TSHR (0.46) | KDM4EMAPK1TDP1PPARGHRH3 | |
| SCHEMBL14330631 | 0.78 | CYP2C9 (0.43) | NPC1MAPTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL3371655 | 0.78 | ALOX5 (0.61) | NPC1RAB9AACHEPPARG | |
| SCHEMBL23412853 | 0.78 | KDM4E (0.49) | NPC1MAPTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL23412329 | 0.77 | PDE3B (0.42) | MAPTKDM4EACHEPPARG | |
| SCHEMBL6359779 | 0.76 | KDM4E (0.54) | NPC1RAB9AKDM4E | |
| SCHEMBL1289697 | 0.76 | ACHE (0.67) | NPC1MAPTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6358875 | 0.75 | ATP4A (0.39) | NPC1MAPTRAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | NPC1 3871/4885MAPT 3729/4885RAB9A 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.